The translocator protein as a drug target in Alzheimer's disease

Expert Review of Neurotherapeutics

Volumn 14, Issue 4, 2014, Pages 439-448

  Chua, Sook W ^a,b   Kassiou, Michael ^b,c   Ittner, Lars M ^a,d  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

Alzheimer's disease; Drug development; Microglia; Neuroinflammation; Positron emission topography; Translocator protein; TSPO

Indexed keywords

4' CHLORODIAZEPAM; ACETAMIDE DERIVATIVE; ALPIDEM; AMYLOID BETA PROTEIN; CARBON 11; CARRIER PROTEIN; DPA 714; EMAPUNIL; IODINE 125; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; PYRIMIDINE DERIVATIVE; RADIOLIGAND; SSR 180575; TAU PROTEIN; UNCLASSIFIED DRUG; VINPOCETINE;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ASTROCYTE; ASTROCYTOSIS; BINDING AFFINITY; DRUG STRUCTURE; DRUG TARGETING; GLIOSIS; HUMAN; LIGAND BINDING; LIPOPHILICITY; MICROGLIA; MITOCHONDRION; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; TOPOGRAPHY; UPREGULATION;

ALZHEIMER DISEASE; ANIMALS; ANTIPSYCHOTIC AGENTS; HUMANS; RECEPTORS, GABA;

EID: 84896333770     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2014.896201     Document Type: Review

References (112)

1. Braestrup C, Squires RF. Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding. Proc Natl Acad Sci USA 1977; 74(9):3805-9
2. de Souza EB, Anholt RR, Murphy KM, et al. Peripheral-type benzodiazepine receptors in endocrine organs: autoradiographic localization in rat pituitary, adrenal, and testis. Endocrinology 1985; 116(2):567-73
3. Anholt RR, de Souza EB, Oster-Granite ML, Snyder SH. Peripheral-type benzodiazepine receptors: autoradiographic localization in whole-body sections of neonatal rats. J Pharmacol Exp Ther 1985;233(2):517-26
4. Antkiewicz-Michaluk L, Guidotti A, Krueger KE. Molecular characterization and mitochondrial density of a recognition site for peripheral-type benzodiazepine ligands. Mol Pharmacol 1988;34(3):272-8
5. Papadopoulos V, Baraldi M, Guilarte TR, et al. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 2006;27(8):402-9
6. Schoemaker H, Boles RG, Horst WD, Yamamura HI. Specific high-affinity binding sites for [3H]Ro 5-4864 in rat brain and kidney. J Pharmacol Exp Ther 1983;225(1):61-9
7. Krueger KE, Papadopoulos V. Mitochondrial benzodiazepine receptors and the regulation of steroid biosynthesis. Annu Rev Pharmacol Toxicol 1992;32:211-37
8. Marangos PJ, Patel J, Boulenger JP, Clark-Rosenberg R. Characterization of peripheral-type benzodiazepine binding sites in brain using [3H]Ro 5-4864. Mol Pharmacol 1982;22(1):26-32
9. Hardwick M, Fertikh D, Culty M, et al. Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol. Cancer Res 1999;59(4):831-42
10. Olson JM, Ciliax BJ, Mancini WR, Young AB. Presence of peripheral-type benzodiazepine binding sites on human erythrocyte membranes. Eur J Pharmacol 1988;152(1-2):47-53
11. Oke BO, Suarez-Quian CA, Riond J, et al. Cell surface localization of the peripheral-type benzodiazepine receptor (PBR) in adrenal cortex. Mol Cell Endocrinol 1992;87(1-3):R1-6
12. Doble A, Benavides J, Ferris O, et al. Dihydropyridine and peripheral type benzodiazepine binding sites: subcellular distribution and molecular size determination. Eur J Pharmacol 1985; 119(3):153-67
13. Alho H, Varga V, Krueger KE. Expression of mitochondrial benzodiazepine receptor and its putative endogenous ligand diazepam binding inhibitor in cultured primary astrocytes and C-6 cells: relation to cell growth. Cell Growth Differ 1994;5(9): 1005-14
14. Gavish M, Bachman I, Shoukrun R, et al. Enigma of the peripheral benzodiazepine receptor. Pharmacol Rev 1999;51(4):629-50
15. Li F, Xia Y, Meiler J, Ferguson-Miller S. Characterization and modeling of the oligomeric state and ligand binding behavior of purified translocator protein 18 kDa from rhodobacter sphaeroides. Biochemistry 2013;52(34):5884-99
16. Papadopoulos V, Amri H, Boujrad N, et al. Peripheral benzodiazepine receptor in cholesterol transport and steroidogenesis. Steroids 1997;62(1):21-8
17. Sprengel R, Werner P, Seeburg PH, et al. Molecular cloning and expression of cDNA encoding a peripheral-type benzodiazepine receptor. J Biol Chem 1989; 264(34):20415-21
18. Bernassau JM, Reversat JL, Ferrara P, et al. A 3D model of the peripheral benzodiazepine receptor and its implication in intra mitochondrial cholesterol transport. J Mol Graph 1993;11(4):236-44.235
19. Murail S, Robert J-C, Cöc Y-M, et al. Secondary and tertiary structures of the transmembrane domains of the translocator protein TSPO determined by NMR. Stabilization of the TSPO tertiary fold upon ligand binding. Biochim Biophys Acta 2008;1778(6):1375-81
20. Baker ME, Fanestil DD. Mammalian peripheral-type benzodiazepine receptor is homologous to CrtK protein of rhodobacter capsulatus, a photosynthetic bacterium. Cell 1991;65(5):721-2
21. Korkhov VM, Sachse C, Short JM, Tate CG. Three-dimensional structure of TspO by electron cryomicroscopy of helical crystals. Structure 2010;18(6):677-87
22. Rupprecht R, Papadopoulos V, Rammes G, et al. Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders. Nat Rev Drug Discov 2010;9(12):971-88
23. Delavoie F, Li H, Hardwick M, et al. In Vivo and in Vitro Peripheral-Type Benzodiazepine Receptor Polymerization: functional Significance in Drug Ligand and Cholesterol Binding. Biochemistry 2003; 42(15):4506-19
24. Paul SM, Kempner ES, Skolnick P. In situ molecular weight determination of brain and peripheral benzodiazepine binding sites. Eur J Pharmacol 1981;76(4):465-6
25. Antkiewicz-Michaluk L, Mukhin AG, Guidotti A, Krueger KE. Purification and characterization of a protein associated with peripheral-type benzodiazepine binding sites. J Biol Chem 1988;263(33):17317-21
26. Papadopoulos V, Boujrad N, Ikonomovic MD, et al. Topography of the Leydig cell mitochondrial peripheral-type benzodiazepine receptor. Mol Cell Endocrinol 1994;104(1):R5-9
27. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 1999;341(Pt 2):233-49
28. Joseph-Liauzun E, Farges R, Delmas P, et al. The Mr 18,000 subunit of the peripheral-type benzodiazepine receptor exhibits both benzodiazepine and isoquinoline carboxamide binding sites in the absence of the voltage-dependent anion channel or of the adenine nucleotide carrier. J Biol Chem 1997;272(44):28102-6
29. Lacapère JJ, Delavoie F, Li H, et al. Structural and functional study of reconstituted peripheral benzodiazepine receptor. Biochem Biophys Res Commun 2001;284(2):536-41
30. Yeliseev AA, Kaplan S. TspO of rhodobacter sphaeroides. A structural and functional model for the mammalian peripheral benzodiazepine receptor. J Biol Chem 2000;275(8):5657-67
31. Teboul D, Beaufils S, Taveau J-C, et al. Mouse TSPO in a lipid environment interacting with a functionalized monolayer. Biochim Biophys Acta 2012;1818(11): 2791-800
32. Li H, Yao Z, Degenhardt B, et al. Cholesterol binding at the cholesterol recognition/interaction amino acid consensus (CRAC) of the peripheral-type benzodiazepine receptor and inhibition of steroidogenesis by an HIV TAT-CRAC peptide. Proc Natl Acad Sci USA 2001; 98(3):1267-72
33. Verma A, Nye JS, Snyder SH. Porphyrins are endogenous ligands for the mitochondrial (peripheral-type) benzodiazepine receptor. Proc Natl Acad Sci USA 2007;84(8):2256-60
34. Miettinen H, Kononen J, Haapasalo H, et al. Expression of peripheral-type benzodiazepine receptor and diazepam binding inhibitor in human astrocytomas: relationship to cell proliferation. Cancer Res 1995;55(12):2691-5
35. Anholt RR. Mitochondrial benzodiazepine receptors as potential modulators of intermediary metabolism. Trends Pharmacol Sci 1986;7:506-11
36. Hirsch JD, Beyer CF, Malkowitz L, et al. Mitochondrial benzodiazepine receptors mediate inhibition of mitochondrial respiratory control. Mol Pharmacol 1989; 35(1):157-63
37. Kugler W, Veenman L, Shandalov Y, et al. Ligands of the mitochondrial 18 kDa translocator protein attenuate apoptosis of human glioblastoma cells exposed to erucylphosphohomocholine. Cell Oncol 2008;30(5):435-50
38. Veiga S, Carrero P, Pernia O, et al. Translocator protein 18 kDa is involved in the regulation of reactive gliosis. Glia 2007; 55(14):1426-36
39. Mukhin AG, Papadopoulos V, Costa E, Krueger KE. Mitochondrial benzodiazepine receptors regulate steroid biosynthesis. Proc Natl Acad Sci USA 1989;86(24):9813-16
40. Taketani S, Kohno H, Furukawa T, Tokunaga R. Involvement of peripheral-type benzodiazepine receptors in the intracellular transport of heme and porphyrins. J Biochem 1995;117(4):875-80
41. Papadopoulos V, Lecanu L. Translocator protein (18 kDa) TSPO: an emerging therapeutic target in neurotrauma. Exp Neurol 2009;219(1):53-7
42. Scarf AM, Ittner LM, Kassiou M. The translocator protein (18 kDa): central nervous system disease and drug design. J Med Chem 2009;52(3):581-92
43. Hauet T, Yao Z-X, Bose HS, et al. Peripheral-type benzodiazepine receptor-mediated action of steroidogenic acute regulatory protein on cholesterol entry into leydig cell mitochondria. Mol Endocrinol 2005;19(2):540-54
44. Papadopoulos V, Guarneri P, Kreuger KE, et al. Pregnenolone biosynthesis in C6-2B glioma cell mitochondria: regulation by a mitochondrial diazepam binding inhibitor receptor. Proc Natl Acad Sci USA 1992; 89(11):5113-17
45. Li H, Papadopoulos V. Peripheral-type benzodiazepine receptor function in cholesterol transport. Identification of a putative cholesterol recognition/interaction amino acid sequence and consensus pattern. Endocrinology 1998;139(12):4991-7
46. Morohaku K, Pelton SH, Daugherty DJ, et al. Translocator protein/peripheral benzodiazepine receptor is not required for steroid hormone biosynthesis. Endocrinology 2014;155(1):89-97
47. Casellas P, Galiegue S, Basile AS. Peripheral benzodiazepine receptors and mitochondrial function. Neurochem Int 2002;40(6): 475-86
48. Ricchelli F, S ? ileikyte? J, Bernardi P. Shedding light on the mitochondrial permeability transition. Biochim Biophys Acta 2011;1807(5):482-90
49. Awad M, Gavish M. Differential effect of detergents on [3H]Ro 5-4864 and [3H]PK 11195 binding to peripheral-type benzodiazepine-binding sites. Life Sci 1988; 43(2):167-75
50. Le Fur G, Vaucher N, Perrier ML, et al. Differentiation between two ligands for peripheral benzodiazepine binding sites, [3H]RO5-4864 and [3H]PK 11195, by thermodynamic studies. Life Sci 1983;33(5): 449-57
51. Awad M, Gavish M. Binding of [3H]Ro 5-4864 and [3H]PK 11195 to cerebral cortex and peripheral tissues of various species: species differences and heterogeneity in peripheral benzodiazepine binding sites. J Neurochem 1987;49(5):1407-14
52. James ML, Selleri S, Kassiou M. Development of ligands for the peripheral benzodiazepine receptor. Curr Med Chem 2006;13(17):1991-2001
53. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82(4):239-59
54. Ballatore C, Lee VM-Y, Trojanowski JQ. Tau-mediated neurodegeneration in Alzheimer's disease and related disorders. Nat Rev Neurosci 2007;8(9):663-72
55. Querfurth HW, LaFerla FM. Alzheimer's Disease. N Engl J Med 2010;362(4):329-44
56. Haass C, Selkoe DJ. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid b-peptide. Nat Rev Mol Cell Biol 2007;8(2):101-12
57. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev 2001; 81(2):741-66
58. Ittner LM, Götz J. Amyloid-b and tau-a toxic pas de deux in Alzheimer's disease. Nat Rev Neurosci 2011;12(2):65-72
59. Hirai K, Aliev G, Nunomura A, et al. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 2001;21(9):3017-23
60. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006; 443(7113):787-95
61. Eckert A, Schulz KL, Rhein V, Götz J. Convergence of amyloid-b and tau pathologies on mitochondria in vivo. Mol Neurobiol 2010;41(2-3):107-14
62. Manczak M, Anekonda TS, Henson E, et al. Mitochondria are a direct site of Ab accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 2006;15(9): 1437-49
63. Du H, Yan SS. Mitochondrial permeability transition pore in Alzheimer's disease: cyclophilin D and amyloid beta. Biochim Biophys Acta BBAMol Basis Dis 2010; 1802(1):198-204
64. David DC. Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem 2005;280(25):23802-14
65. Rhein V, Song X, Wiesner A, et al. Amyloid-b and tau synergistically impair the oxidative phosphorylation system in triple transgenic Alzheimer's disease mice. Proc Natl Acad Sci USA 2009;106(47):20057-62
66. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21(3):383-421
67. Wyss-Coray T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat Med 2006;12(9):1005-15
68. Wyss-Coray T, Rogers J. Inflammation in Alzheimer disease - a brief review of the basic science and clinical literature. Cold Spring Harb Perspect Med 2012;2(1): a006346-6
69. Vehmas AK, Kawas CH, Stewart WF, Troncoso JC. Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging 2003; 24(2):321-31
70. McGeer EG, McGeer PL. Inflammatory processes in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2003;27(5):741-9
71. DeWitt DA, Perry G, Cohen M, et al. Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease. Exp Neurol 1998;149(2):329-40
72. Garwood CJ, Pooler AM, Atherton J, et al. Astrocytes are important mediators of Ab-induced neurotoxicity and tau phosphorylation in primary culture. Cell Death Dis 2011;2:e167
73. Wyss-Coray T, Loike JD, Brionne TC, et al. Adult mouse astrocytes degrade amyloid-b in vitro and in situ. Nat Med 2003;9(4):453-7
74. Ji B, Maeda J, Sawada M, et al. Imaging of peripheral benzodiazepine receptor expression as biomarkers of detrimental versus beneficial glial responses in mouse models of Alzheimer's and other CNS pathologies. J Neurosci 2008;28(47): 12255-67
75. Maeda J, Zhang M-R, Okauchi T, et al. In vivo positron emission tomographic imaging of glial responses to amyloid-beta and tau pathologies in mouse models of Alzheimer's disease and related disorders. J Neurosci 2011;31(12):4720-30
76. Diorio D, Welner SA, Butterworth RF, et al. Peripheral benzodiazepine binding sites in Alzheimer's disease frontal and temporal cortex. Neurobiol Aging 1991; 12(3):255-8
77. Versijpt JJ, Dumont F, Van Laere KJ, et al. Assessment of neuroinflammation and microglial activation in Alzheimer's disease with radiolabelled PK11195 and single photon emission computed tomography. A pilot study. Eur Neurol 2003;50(1):39-47
78. Gulyás B, Makkai B, Kása P, et al. A comparative autoradiography study in post mortem whole hemisphere human brain slices taken from Alzheimer patients and age-matched controls using two radiolabelled DAA1106 analogues with high affinity to the peripheral benzodiazepine receptor (PBR) system. Neurochem Int 2009;54(1):28-36
79. Venneti S, Lopresti BJ, Wang G, et al. PK11195 labels activated microglia in Alzheimer's disease and in vivo in a mouse model using PET. Neurobiol Aging 2009; 30(8):1217-26
80. CAGNIN A, Brooks DJ, Kennedy AM, et al. In-vivo measurement of activated microglia in dementia. Lancet 2001; 358(9280):461-7
81. Venneti S, Wiley CA, Kofler J. Imaging microglial activation during neuroinflammation and Alzheimer's disease. J Neuroimmune Pharmacol 2009;4(2): 227-43
82. Mattner F, Bandin DL, Staykova M, et al. Evaluation of [123I]-CLINDE as a potent SPECT radiotracer to assess the degree of astroglia activation in cuprizone-induced neuroinflammation. Eur J Nucl Med Mol Imaging 2011;38(8):1516-28
83. James ML, Fulton RR, Henderson DJ, et al. Synthesis and in vivo evaluation of a novel peripheral benzodiazepine receptor PET radioligand. Bioorg Med Chem 2005; 13(22):6188-94
84. Venneti S, Lopresti BJ, Wiley CA. Molecular imaging of microglia/ macrophages in the brain. Glia 2012;61(1): 10-23
85. Venneti S, Wang G, Nguyen J, Wiley CA. The positron emission tomography ligand DAA1106 binds with high affinity to activated microglia in human neurological disorders. J Neuropathol Exp Neurol 2008; 67(10):1001-10
86. Vowinckel E, Reutens D, Becher B, et al. PK11195 binding to the peripheral benzodiazepine receptor as a marker of microglia activation in multiple sclerosis and experimental autoimmune encephalomyelitis. J Neurosci Res 1997; 50(2):345-53
87. Banati RB, Newcombe J, Gunn RN, et al. The peripheral benzodiazepine binding site in the brain in multiple sclerosis: quantitative in vivo imaging of microglia as a measure of disease activity. Brain 2000; 123(Pt 11):2321-37
88. Itzhak Y, Baker L, Norenberg MD. Characterization of the peripheral-type benzodiazepine receptors in cultured astrocytes: evidence for multiplicity. Glia 1993;9(3):211-18
89. Park CH, Carboni E, Wood PL, Gee KW. Characterization of peripheral benzodiazepine type sites in a cultured murine BV-2 microglial cell line. Glia 1996; 16(1):65-70
90. Lavisse S, Guillermier M, Herard AS, et al. Reactive astrocytes overexpress TSPO and are detected by TSPO positron emission tomography imaging. J Neurosci 2012; 32(32):10809-18
91. Stephenson DT, Schober DA, Smalstig EB, et al. Peripheral benzodiazepine receptors are colocalized with activated microglia following transient global forebrain ischemia in the rat. J Neurosci 1995;15(7):5263-74
92. Choi J, Ifuku M, Noda M, Guilarte TR. Translocator protein (18 kDa)/peripheral benzodiazepine receptor specific ligands induce microglia functions consistent with an activated state. Glia 2011;59(2):219-30
93. Kreisl WC, Lyoo CH, McGwier M, et al. In vivo radioligand binding to translocator protein correlates with severity of Alzheimer's disease. Brain 2013;136(7): 2228-38
94. Edison P, Archer HA, Gerhard A, et al. Microglia, amyloid, and cognition in Alzheimer's disease: an [11C](R)PK11195- PET and [11C]PIB-PET study. Neurobiol Dis 2008;32(3):412-19
95. Schuitemaker A, Kropholler MA, Boellaard R, et al. Microglial activation in Alzheimer's disease: an (R)-[11C] PK11195 positron emission tomography study. Neurobiol Aging 2013;34(1):128-36
96. Wiley CA, Lopresti BJ, Venneti S, et al. Carbon 11-labeled Pittsburgh Compound B and carbon 11-labeled (R)- PK11195 positron emission tomographic imaging in Alzheimer disease. Arch Neurol 2009;66(1):60-7
97. Okello A, Edison P, Archer HA, et al. Microglial activation and amyloid deposition in mild cognitive impairment: a PET study. Neurology 2009;72(1):56-62
98. Varrone A, Mattsson P, Forsberg A, et al. In vivo imaging of the 18-kDa translocator protein (TSPO) with [18F] FEDAA1106 and PET does not show increased binding in Alzheimer's disease patients. Eur J Nucl Med Mol Imaging 2013;40(6):921-31
99. Gulyás B, Vas A, Tóth M, et al. Age and disease related changes in the translocator protein (TSPO) system in the human brain: positron emission tomography measurements with [11C]vinpocetine. Neuroimage 2011;56(3):1111-21
100. Owen DR, Yeo AJ, Gunn RN, et al. An 18-kDa translocator protein (TSPO) polymorphism explains differences in binding affinity of the PET radioligand PBR28. J Cereb Blood Flow Metab 2012; 32(1):1-5
101. Owen DR, Howell OW, Tang S-P, et al. Two binding sites for [3H]PBR28 in human brain: implications for TSPO PET imaging of neuroinflammation. J Cereb Blood Flow Metab 2010;30(9):1608-18
102. Kreisl WC, Jenko KJ, Hines CS, et al. A genetic polymorphism for translocator protein 18 kDa affects both in vitro and in vivo radioligand binding in human brain to this putative biomarker of neuroinflammation. J Cereb Blood Flow Metab 2013;33(1):53-8
103. Rupprecht R, Rammes G, Eser D, et al. Translocator Protein (18 kD) as Target for Anxiolytics Without Benzodiazepine-Like Side Effects. Science 2009;325(5939):490-3
104. Aouad M, Zell V, Juif P-E, et al. Etifoxine analgesia in experimental monoarthritis: a combined action that protects spinal inhibition and limits central inflammatory processes. Pain 2014;155(2):403-12
105. Trophos announces results of phase 3 study of olesoxime in amyotrophic lateral sclerosis www.trophos.com [Internet]. Trophos. Available from: www.trophos.com/news/ pr20111213.htm
106. Trophos completes pivotal phase II/III study of olesoxime in spinal muscular atrophy (SMA) www.trophos.com [Internet]. Trophos. Available from: www.trophos.com/ news/pr20131105.htm
107. Owen DR, Rupprecht R, Nutt DJ. Stratified medicine in psychiatry: a worrying example or new opportunity in the treatment of anxiety? J Psychopharmacol 2013;27(2):119-22
108. Soustiel JF, Zaaroor M, Vlodavsky E, et al. Neuroprotective effect of Ro5-4864 following brain injury. Exp Neurol 2008;214(2):201-8
109. Giatti S, Pesaresi M, Cavaletti G, et al. Neuroprotective effects of a ligand of translocator protein-18 kDa (Ro5-4864) in experimental diabetic neuropathy. Neuroscience 2009;164(2):520-9
110. Ryu JK, Choi HB, McLarnon JG. Peripheral benzodiazepine receptor ligand PK11195 reduces microglial activation and neuronal death in quinolinic acid-injected rat striatum. Neurobiol Dis 2005;20(2): 550-61
111. Leaver KR, Reynolds A, Bodard S, et al. Effects of translocator protein (18 kDa) ligands on microglial activation and neuronal death in the quinolinic-acid-injected rat striatum. ACS Chem Neurosci 2012;3(2):114-19
112. Barron AM, Garcia-Segura LM, Caruso D, et al. Ligand for translocator protein reverses pathology in a mouse model of Alzheimer's disease. J Neurosci 2013;33(20):8891-7